undamentalytics Newsletter
Sign in

Axogen, Inc. balance sheet

At the end of fiscal 2025, Axogen, Inc. had total assets of $222m, total liabilities of $92.8m and shareholders' equity of $129m. It held $35.5m in cash against $48.4m of debt: net debt of $12.8m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents28142082630372436493315312836329
Receivables011235811151718182225242634
Inventory22333457121413171923334249
Total current assets511182614354456151135145127988899120438
Goodwill00———————————————
Total assets612202816374659160155201208195197204222550
Accounts payable0——11243585691283—
Deferred revenue (current)———000000000—————
Total current liabilities9212241114132123242430312436
Short-term debt70————0102———————
Long-term debt04222525252020003245464747480
Total debt75222525252425023545464747480
Total liabilities18623282829313413227895941011009354
Shareholders' equity−276−30−118152514713212311310196104129496
Non-controlling interests and other (assets − liabilities − equity)15————————————————
Net debt (negative = net cash)5−38517−1−6−12−24−34−141230162013−329
Shares outstanding1m11m11m—19m30m33m34m39m40m41m42m42m43m44m47m60m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AXGN vs KIDSAXGN vs LMATAXGN vs CERSAXGN vs SKIN

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Axogen, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Axogen, Inc.